Daewoong Pharmaceutical and DNC Esthetics Share Customized Treatment Strategies for Patients in Their 40s

Daewoong Pharmaceutical and DNC Esthetics held the 'Deep Symposium' event on the 31st of last month at the JW Marriott Hotel in Seoul. Photo by Daewoong Pharmaceutical

Daewoong Pharmaceutical and DNC Esthetics unveiled customized treatment strategies for individuals in their 40s, drawing enthusiastic responses from the audience with an interactive program.

On June 2, Daewoong Pharmaceutical and DNC Esthetics announced that they held the 'Deep (Daewoong·DNC Medical-AEsthetic Expert Program) Symposium' over two days, starting on May 31, at the JW Marriott Hotel in Seoul.

This symposium focused on the demographic in their 40s. The event highlighted optimized treatment strategies tailored to the unique characteristics of this age group, who often experience multiple aging symptoms simultaneously, such as decreased skin elasticity, volume loss, and localized fat accumulation.

The core of the symposium was its interactive program. Participants took part in panel discussions where they collaborated with presenters to develop treatment plans, and then joined a 'dual live broadcast' session to observe the results in real time. Throughout this process, various combinations of Daewoong’s leading aesthetic products and actual clinical data were shared, allowing participants to concretely define the expected effects and strategies of the treatments.

Additionally, lectures covered a range of topics, including 'Creating a Youthful 40s with Nabota, Viollet, and Declasy,' as well as facial lifting using lifting threads and fillers. Live demonstrations were also conducted, enhancing participants’ practical understanding.

Lee Jonghun, director of Lizbell Clinic, stated, "The 40s are a period when skin elasticity decreases and volume loss occurs simultaneously, so the right combination of products and timing of treatments is crucial. Volumizing and collagen regeneration-focused combination procedures using Daewoong’s diverse aesthetic lineup are effective in achieving a natural and youthful appearance."

Jang Dooyeol, director of Change Clinic, also emphasized, "People in their 40s require both lifting and volume improvement at the same time, so a comprehensive approach determines the completeness of the treatment. Dous and Declasy are product combinations optimized for such complex treatment strategies."

At the event, clinical cases and product combinations based on these expert-recommended combination strategies were shared in real time, increasing the participants’ ability to apply them in practice.

Yoon Junsoo, head of Daewoong Pharmaceutical’s Nabota Business Division, commented, "This event was significant in that medical professionals directly participated in developing optimized treatment strategies for patients in their 40s. We will continue to deliver practical clinical value to aesthetic professionals through various programs."

Meanwhile, Daewoong Pharmaceutical continues to expand its presence in both domestic and international markets with a diverse medical aesthetics lineup, including 'Nabota,' the first botulinum toxin in Asia to receive U.S. FDA approval, 'Viollet,' Korea’s first locally developed fat-dissolving injection, the filler 'Declasy,' and the suture thread 'Dous.'